IRIS
STELLA, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.360
EU - Europa 2.184
AS - Asia 1.675
SA - Sud America 354
AF - Africa 289
OC - Oceania 1
Totale 7.863
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.266
SG - Singapore 875
RU - Federazione Russa 871
IT - Italia 655
CN - Cina 413
BR - Brasile 322
IE - Irlanda 219
CI - Costa d'Avorio 184
IN - India 116
VN - Vietnam 91
UA - Ucraina 81
DE - Germania 80
CA - Canada 65
SN - Senegal 59
GB - Regno Unito 52
KR - Corea 44
FI - Finlandia 39
SE - Svezia 33
PL - Polonia 27
BE - Belgio 22
ES - Italia 21
MX - Messico 20
FR - Francia 19
JP - Giappone 19
AR - Argentina 18
TR - Turchia 17
IQ - Iraq 16
NL - Olanda 16
ZA - Sudafrica 16
BD - Bangladesh 15
CZ - Repubblica Ceca 14
HK - Hong Kong 11
UZ - Uzbekistan 11
ID - Indonesia 9
CH - Svizzera 8
IL - Israele 8
NG - Nigeria 8
MA - Marocco 7
AE - Emirati Arabi Uniti 6
AT - Austria 6
IR - Iran 6
GR - Grecia 5
EC - Ecuador 4
KE - Kenya 4
KZ - Kazakistan 4
NO - Norvegia 4
TN - Tunisia 4
BJ - Benin 3
DO - Repubblica Dominicana 3
PY - Paraguay 3
SA - Arabia Saudita 3
AZ - Azerbaigian 2
BG - Bulgaria 2
CO - Colombia 2
EG - Egitto 2
HU - Ungheria 2
LB - Libano 2
LT - Lituania 2
PE - Perù 2
RS - Serbia 2
TT - Trinidad e Tobago 2
VE - Venezuela 2
AM - Armenia 1
AU - Australia 1
CG - Congo 1
GD - Grenada 1
GL - Groenlandia 1
HN - Honduras 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
LV - Lettonia 1
MY - Malesia 1
NA - Namibia 1
NP - Nepal 1
PK - Pakistan 1
PS - Palestinian Territory 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UY - Uruguay 1
Totale 7.863
Salva come PNG Salva come JPEG
Città #
Singapore 556
Santa Clara 517
Dallas 477
Moscow 430
Chandler 326
Chicago 231
Dublin 219
Ashburn 199
Catania 187
Abidjan 184
San Jose 157
Jacksonville 96
Beijing 90
Los Angeles 88
Hefei 85
Boardman 84
Kochi 79
Cambridge 60
Lawrence 59
Dakar 58
Andover 55
Civitanova Marche 54
New York 50
Seoul 43
Palermo 38
Grafing 35
Nanjing 34
Des Moines 30
São Paulo 30
Buffalo 29
Wilmington 29
Milan 28
The Dalles 27
Toronto 27
Dong Ket 26
Columbus 25
Brussels 22
Turku 22
Warsaw 21
Orem 20
Rome 20
Council Bluffs 19
Ho Chi Minh City 19
Montreal 19
Munich 19
Tokyo 19
Hanoi 18
Bari 16
Chennai 16
Johannesburg 14
Brno 13
Messina 13
San Mateo 13
Seattle 13
Stockholm 13
Lappeenranta 12
Santa Venerina 12
Belo Horizonte 11
Brooklyn 11
Jiaxing 11
Nanchang 11
Ottawa 11
Rio de Janeiro 11
Boston 10
Falls Church 10
London 10
Aci Catena 9
Bremen 9
Hong Kong 9
Saint Petersburg 9
Abuja 8
Curitiba 8
Houston 8
Manchester 8
Phoenix 8
Amsterdam 7
Brasília 7
Denver 7
Hanover 7
Hebei 7
Poplar 7
Pune 7
Querétaro 7
Redmond 7
San Francisco 7
Tashkent 7
Atlanta 6
Florence 6
Jakarta 6
Miami 6
Redondo Beach 6
Scottsdale 6
Baghdad 5
Fairfield 5
Frankfurt am Main 5
Giardini-Naxos 5
Helsinki 5
Manaus 5
Mascalucia 5
Mexico City 5
Totale 5.420
Salva come PNG Salva come JPEG
Nome #
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 214
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 164
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 163
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? 158
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 156
Biomarkers and prognostic factors for malignant pleural mesothelioma 154
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 153
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 152
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 151
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 149
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 149
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 145
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 141
A case of high-risk AML in a patient with advanced systemic mastocytosis 139
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 139
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 139
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 137
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 136
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 136
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma 135
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 132
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 132
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity 131
Rufloxacin induced photosensitization in bio-models of increasing complexity 129
New insights in thyroid cancer and p53 family proteins 122
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 122
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 119
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 115
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 115
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 114
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 113
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 111
Opportunities and challenges of liquid biopsy in thyroid cancer 110
Double-face activity of resveratrol in voluntary runners: assessment of DNA damage by comet assay. 109
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study 108
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 108
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 106
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma 105
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 105
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 103
Uncommon long-term survival in a patient with chronic myeloid leukemia 101
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 101
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 101
In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients 100
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 99
Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients 98
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 98
Approcci Terapeutici Innovativi per il Trattamento di Cellule di Leucemia Mieloide Cronica Resistenti ad Imatinib Mesilato 97
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 97
A Multiplex Assay for Fast PIK3CA Hotspot Mutation Characterization in a Single Specimen by 3-Color Digital PCR Analysis 96
Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51 92
THE ROLE OF SPARC IN CHRONIC MYELOID LEUKEMIA 88
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 88
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 88
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 87
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 87
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 85
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 84
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer 81
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 81
The Role of New Technologies in Myeloproliferative Neoplasms 80
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 78
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 78
REThinking the role of the RET oncogene in breast cancer 74
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 74
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 73
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 68
Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment 67
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis 64
The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities 63
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain 60
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes 59
Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer 37
Totale 8.043
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.222
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.222
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021153 0 0 0 0 0 0 27 2 53 3 33 35
2021/2022435 20 67 11 7 78 8 64 15 25 11 30 99
2022/20231.036 68 82 56 119 58 148 13 201 209 14 46 22
2023/2024553 44 83 26 24 19 132 8 33 7 23 112 42
2024/20252.107 30 330 79 152 412 291 166 64 75 143 255 110
2025/20263.274 253 240 584 288 657 1.041 211 0 0 0 0 0
Totale 8.043